MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...
MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. Background: IMP321 is a recombinant soluble LAG-3Ig fusion ...
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...
TACTI-004 trial evaluates efti with Keytruda and chemotherapy for advanced NSCLC, focusing on progression-free and overall survival. Efti's unique MHC Class 2 agonist mechanism shows strong efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback